ClinicalTrials.gov URL
Acknowledgement
3 business days
EA Therapies for Single Patient
Uproleselan for use in combination with chemotherapy for treatment of adult patients with relapsed or refractory acute myeloid leukemia.
EA Policies for Single Patient
GlycoMimetics considers expanded access requests on a case-by-case basis. Consideration factors include: the patient’s ability and eligibility to participate in an ongoing trial, drug supply and availability, the treating physician’s benefit-to-risk analysis, and institutional experience with the drug, among others.